Investor Update October 30, 2017 Kevin Ballinger Executive Vice - - PowerPoint PPT Presentation

investor update
SMART_READER_LITE
LIVE PREVIEW

Investor Update October 30, 2017 Kevin Ballinger Executive Vice - - PowerPoint PPT Presentation

Transcatheter Cardiovascular Therapeutics Investor Update October 30, 2017 Kevin Ballinger Executive Vice President and President, Interventional Cardiology Professor Ian Meredith, A.M. Executive Vice President and Global Chief Medical Officer


slide-1
SLIDE 1

1

Transcatheter Cardiovascular Therapeutics

Investor Update

October 30, 2017 Kevin Ballinger Executive Vice President and President, Interventional Cardiology Professor Ian Meredith, A.M. Executive Vice President and Global Chief Medical Officer Nicholas Spadea-Anello Structural Heart-LAAC Vice President and General Manager

slide-2
SLIDE 2

2 2

Safe Harbor for Forward-Looking Statements and Regulatory Disclaimers

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act

  • f 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be

identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “estimate,” “intend” and similar

  • words. These forward-looking statements are based on our beliefs, assumptions and estimates using

information available to us at the time and are not intended to be guarantees of future events or

  • performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties

materialize, actual results could differ materially from the expectations and projections expressed or implied by our forward-looking statements. Factors that may cause such differences can be found in our most recent Form 10-K and Forms 10-Q filed or to be filed with the Securities and Exchange Commission under the headings “Risk Factors” and “Safe Harbor for Forward-Looking Statements.” Accordingly, you are cautioned not to place undue reliance on any of our forward-looking statements. We disclaim any intention or obligation to publicly update or revise any forward- looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which they may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. Market Estimates: Unless noted otherwise, all references to market sizes, market share positions, and market growth rates are BSX internal estimates. Regulatory Disclaimers: LOTUS EdgeTM and ACURATE neoTM Valves may only be used in countries where they are approved for use. LOTUS Edge Valve and iSLEEVETM are not available for sale in the European Economic Area. For education purposes only. LOTUS EdgeTM Valve and iSLEEVETM are investigational devices in the United States and are not available for sale. WATCHMAN FLXTM is pending CE Mark. Not available for use or sale in the United States.

slide-3
SLIDE 3

3 3

Broadest Portfolio to Drive IC Category Leadership

Structural Heart Coronary Therapies

Stents Complex PCI PCI Guidance TAVR LAAC Mitral

Coronary Therapies Structural Heart Total Cardiology 2016 Market Size $7.5B $3B $10.5B 5yr CAGR (2016-2021) 1% +17% +7%

  • Est. 2021 Market Size

$8.0B $6.5B $14.5B

  • Est. 2021 Share Position

#1 #2 #1

slide-4
SLIDE 4

4 4

Diversifying into Faster Growth IC Markets

54% 36% 10%

~30%

2016

Structural Heart Complex PCI Stents

2021E

Maintain coronary therapies leadership + grow structural heart platforms = healthy IC portfolio diversification

BSX IC Revenue Mix

Market Size = $10.5B Market Size = $14.5B ~40% ~30%

slide-5
SLIDE 5

5 E = expected *Pending

Compelling TAVR Portfolio

5

ACURATE neo™ Aortic Valve System – EU

  • Commercial expansion with ACURATE neo TF and TA
  • Launch next generation ACURATE neo AS H2:18E

LOTUS Edge™ Aortic Valve System

  • EU launch Q1:18E and U.S. launch mid-2018E

Accessory Devices

  • Market leading Safari2™ Guidewire
  • iSLEEVE™ Expandable Sheath

Clinical Programs

  • LOTUS Edge REPRISE IV Intermediate Risk U.S. study
  • Enrollment mid-2018E
  • ACURATE neo U.S. IDE*
  • Enrollment H2:18E

Expand Your Reach

More Options for Better Outcomes

slide-6
SLIDE 6

6

WATCHMAN™ LAAC Device Global Leadership

Commercial Activities

  • Therapy development efforts continue
  • Focus on penetrating U.S. indicated population
  • 1% of penetration = $250M
  • TV campaign showing strong patient activation
  • Pilot market growth is above national average
  • Main CMS DRG for LAAC increased ~11% on Oct 1
  • Received CE Mark for an updated WATCHMAN DFU
  • Allows for DAPT + shorter OAT duration post implant

Clinical Milestones

  • Completed Japan Salute IDE clinical trial in Q3
  • PREVAIL 5-year outcomes highlighted as LBCT Thursday

Product Pipeline

  • WATCHMAN FLX™
  • PINNACLE FLX U.S. IDE – enrollment mid-2018E
  • FLXibility EU Post-Market Study – enrollment mid 2018E

WATCHMAN™

WATCHMAN FLX™

E = expected

slide-7
SLIDE 7

7 7

Unrivaled DES Innovation

  • YTD 2017: DES growth at market rates despite

double digit 2016 growth comparison

  • Comprehensive clinical science:
  • SYNERGY™ studied in ~20,000 patients
  • Unique and differentiated tiered portfolio
  • Future product innovation:
  • 48 mm SYNERGY™
  • 4.5 / 5.0mm SYNERGY™
  • Short DAPT indication
  • Trans-radial enhanced NG DES system

#1

US DES Market Share Strong DES Portfolio and U.S. Market Leader for 14 quarters

slide-8
SLIDE 8

8

Unmatched Complex PCI and Imaging Portfolios

Robust and consistent product cadence continues in 2018 Clear Leadership in $2.5B Complex PCI Market Continued Investment in Imaging Portfolio

New Devices for cPCI

slide-9
SLIDE 9

9

IC Category Leadership via Breadth of Portfolio